Compare HCAI & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCAI | CVKD |
|---|---|---|
| Founded | 2004 | 2022 |
| Country | China | United States |
| Employees | N/A | 5 |
| Industry | Miscellaneous manufacturing industries | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 6.2M |
| IPO Year | N/A | 2022 |
| Metric | HCAI | CVKD |
|---|---|---|
| Price | $4.32 | $2.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 30.5K | ★ 61.9K |
| Earning Date | 05-23-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $63.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $1.86 |
| 52 Week High | $25.99 | $14.64 |
| Indicator | HCAI | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 28.17 | 31.26 |
| Support Level | $0.24 | $1.86 |
| Resistance Level | $9.73 | $3.89 |
| Average True Range (ATR) | 0.62 | 0.20 |
| MACD | -0.22 | 0.04 |
| Stochastic Oscillator | 2.66 | 21.71 |
Huachen AI Parking Management Technology Holding Co Ltd is a comprehensive smart parking solutions and equipment structural parts provider. The company manufactures and offer various cubic parking garage products by employing various working principles, such as lifting and shifting, convenient lifting, vertical circulation, vertical lifting, plane moving, alley stacking, multi-layer cycle, horizontal cycle, and car lift.
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.